Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy

Category Primary study
JournalCancer Research
Year 2013
This article has no abstract
Epistemonikos ID: b2b63d47fccfed4a43482826b491d5e4e4ba85c0
First added on: Feb 06, 2025